PHAR/ 02/02/2026 · 8:02 AM FDA Requests More Data for Joenja in Younger Children with APDS Pharming (PHAR) receives FDA Complete Response Letter for Joenja (leniolisib) in children aged 4-11 with APDS. Additional data needed on dosing and testing methods.